Global Nuclear Medicine/Radiopharmaceuticals Market Expected to Surpass More Than Us$ 4.0 Billion by 2020

Global Nuclear Medicine/Radiopharmaceuticals Market

expected to surpass more than US$ 4.0 billion by 2020

New York, May 26: Market Research Engine has published a new report titled as “Nuclear

Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium,

PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020”

Nuclear medicine is special category in medical branch used for diagnosis and treatment of

disease in a safe and painless way. Nuclear medicine contain radioactive material which

combined called as radiopharmaceutical. The small quantity of radiopharmaceutical is given

into human body in the form of injection or swallowing. It goes to specific location of a body

where there could be disease or abnormality. It emits radiation called gamma rays and

contains gamma camera which helps nuclear medicine physician to see inside the body. It

takes pictures of inner body which helps physician to diagnose patients’ disease.

Browse Full Report: http://www.marketresearchengine.com/reportdetails/nuclearmedicine-market

The nuclear medicine market is expected to exceed more than US$ 4.0 billion by

2020 growing at around 9.0% CAGR for the given forecast period. The important

factors driving the nuclear medicine market are advances in radiotracers and alpha radio

immunotherapy-based targeted cancer treatment. SPECT and PET scans usage has been

increasing to detect diseases like cancer which is driving the nuclear medicine market.

Raising the incidence of cancer and cardiac ailments are also responsible for growing the

nuclear medicine market. The nuclear medicine market is also having some restraints such

as strict regulatory and global Good Manufacturing Practice guidelines. One of the major

restraint is that most of the hospital still rely on conventional diagnostic procedures and not

able to shift to nuclear medicine due to cost...